Non-vitamin K antagonist oral anticoagulants (NOACs) post-percutaneous coronary intervention: a network meta-analysis-Reference-Cited by-同舟云学术

Non-vitamin K antagonist oral anticoagulants (NOACs) post-percutaneous coronary intervention: a network meta-analysis

Published:2019-12-20 Issue:3 Volume:2021 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Al Said Samer¹,Alabed Samer²,Kaier Klaus³,Tan Audrey R⁴,Bode Christoph⁵,Meerpohl Joerg J⁶,Duerschmied Daniel⁵

Affiliation:

1. Department for Internal Medicine III Cardiology Angiology and Pneumology; University Hospital Heidelberg; Heidelberg Germany

2. Infection, Immunity & Cardiovascular Disease; University of Sheffield; Sheffield UK

3. Institute for Medical Biometry and Statistics; Faculty of Medicine and Medical Center, University of Freiburg; Freiburg Germany

4. Institute of Health Informatics Research; University College London; London UK

5. Department of Cardiology and Angiology I, Heart Center; University of Freiburg; Freiburg Germany

6. Institute for Evidence in Medicine; Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg; Freiburg Germany

Publisher

Wiley

Subject

Pharmacology (medical)

Link

https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013252.pub2/epdf/full

Reference148 articles.

1. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation;Lopes;New England Journal of Medicine,2019

2. An open-Label, 2 x 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: rationale and design of the AUGUSTUS trial;Lopes;American Heart Journal,2018

3. A study of apixaban in patients with atrial fibrillation, not caused by a heart valve problem, who are at risk for thrombosis (blood clots) due to having had a recent coronary event, such as a heart attack or a procedure to open the vessels of the heart clinicaltrials.gov/show/nct02415400

4. Apixaban versus warfarin in patients with atrial fibrillation;Granger;New England Journal of Medicine,2011

5. Percutaneous coronary intervention and antiplatelet therapy in patients with atrial fibrillation receiving apixaban or warfarin: insights from the ARISTOTLE trial;Kopin;American Heart Journal,2018

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety outcomes of direct oral anticoagulants in older adults with atrial fibrillation: a systematic review and meta-analysis of (subgroup analyses from) randomized controlled trials;GeroScience;2023-06-01

2. New Oral Anticoagulants for Venous Thromboembolism Prophylaxis in Total Hip and Knee Arthroplasty: A Systematic Review and Network Meta-Analysis;Frontiers in Pharmacology;2022-01-17

3. For adults post percutaneous coronary intervention (PCI), how do different oral anticoagulants compare?;Cochrane Clinical Answers;2020-11-25

4. Non-vitamin K antagonist oral anticoagulants (NOACs) after transcatheter aortic valve replacement (TAVR): a network meta-analysis;Cochrane Database of Systematic Reviews;2020-10-01

5. Meta-Analysis Comparing Potent Oral P2Y12 Inhibitors versus Clopidogrel in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention;American Journal of Cardiovascular Drugs;2020-09-08